医学文献 >>
  • 检索发现
  • 增强检索
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
默认
×
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study.

广告
第一作者: Christoph,Wanner
第一单位: Department of Medicine, Division of Nephrology, University Hospital Würzburg, Oberduerrbacher Str. 6, 97080 Würzburg, Germany.
作者单位: Department of Medicine, Division of Nephrology, University Hospital Würzburg, Oberduerrbacher Str. 6, 97080 Würzburg, Germany. [1] Division of Genetics and Genomic Medicine, Department of Pediatrics, University of California, Irvine, 333 The City Blvd. West, Suite 800, Orange, CA 92868, USA. [2] Foundation for the Study of Neurometabolic Diseases, FESEN, Uriarte 2383, C1425 CABA, Buenos Aires, Argentina. [3] University of Alabama at Birmingham, 1720 University Blvd, Birmingham, AL 35294, USA. [4] Department of Neurology, University Hospital of Würzburg, Oberduerrbacher Str. 6, 97080 Würzburg, Germany. [5] Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil, Switzerland. [6] University College London and Royal Free Hospital, Pond Street, London NW3 2QG, United Kingdom. [7]
关键词 AE, adverse eventBPI-SF, Brief Pain Inventory-Short FormBPI-SF3, Brief Pain Inventory-Short Form item 3BSS, Bristol stool scaleCD, cognitive debriefingCE, concept elicitationCESD-R-20, Center for Epidemiologic Studies Depression Scale RevisedCKD-EPI, Chronic Kidney Disease Epidemiology CollaborationCTCAE, Common Terminology Criteria for Adverse EventsECG, electrocardiographyEOS, end of studyEOT, end-of-treatmentERT, enzyme replacement therapyFABPRO-GI, FABry Disease Patient-Reported Outcome-GastroIntestinalFD, Fabry diseaseFGID, functional gastrointestinal disordersFabry diseaseGCS, glucosylceramide synthaseGI, gastrointestinalGSRS, Gastrointestinal Symptom Rating ScaleGb3, globotriaosylceramideHbA1c, hemoglobin A1cIBS, irritable bowel syndromeIRB, independent review boardLVEF, left ventricular ejection fractionLVMI, left ventricular mass indexLucerastatMODIFYNPSI, neuropathic pain symptom inventoryNRS-11, 11-point numerical rating scaleNYHA, New York Heart AssociationNeP, neuropathic painOLE, open-label extensionPGIC-DS, Patient Global Impression of Change in Disease SeverityPGIC-PS, Patient Global Impression of Change in neuropathic Pain SeverityPGIS-D, Patient Global Impression of Severity of DiseasePGIS-P, Patient Global Impression of Severity of neuropathic painPK, pharmacokineticsPRO, patient-reported outcomeSD, standard deviationSF-36v2, 36-Item Short Form Health Survey Version 2SRT, substrate reduction therapySubstrate reduction therapyUCI, University of California, IrvineUT, usability testingb.i.d., twice dailyeGFR, estimated glomerular filtration rateα-GAL A, lysosomal enzyme α-galactosidase
DOI 10.1016/j.ymgmr.2022.100862
PMID 35782623
发布时间 2022-07-16
提交
  • 浏览4
Molecular genetics and metabolism reports

Molecular genetics and metabolism reports

2022年31卷

100862页

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

官方微信
万方医学小程序
new翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷